Review Article

[Retracted] VEGF Genetic Polymorphisms May Contribute to the Risk of Diabetic Nephropathy in Patients with Diabetes Mellitus: A Meta-Analysis

Table 2

Meta-analysis of the relationships of VEGF genetic polymorphisms with the risk of diabetic nephropathy in patients with diabetes mellitus.

M allele vs. W alleleWM + MM vs. WWMM vs. WW + WM MM vs. WWMM vs. WM
(Allele model)(Dominant model)(Recessive model)(Homozygous model)(Heterozygous model)
OR95% CIP OR95% CIP OR95% CIP OR95% CIP OR95% CIP

Overall1.171.05−1.290.0041.201.04−1.390.0101.171.02−1.340.0301.291.06−1.560.0101.120.98−1.280.103

SNP
rs6921438 Y/X0.880.76−1.040.1300.830.65−1.060.1290.880.67−1.160.3660.790.58−1.090.1520.940.70−1.260.682
rs10738760 Y/X1.080.93−1.270.3161.130.88−1.450.3391.090.84−1.410.5221.160.85−1.580.3371.050.79−1.380.751
rs2010963 G/C1.261.05−1.520.0151.291.05−1.590.0151.441.00−2.050.0471.651.08−2.500.0201.280.94−1.740.115
rs699947 G/A1.040.85−1.290.6680.950.69−1.300.7361.220.85−1.750.2881.150.75−1.760.5161.290.86−1.960.223
rs3025039 C/T1.381.06−1.800.0181.531.02−2.270.0371.390.98−1.980.0621.561.06−2.300.0231.270.87−1.840.210
rs833061 C/T1.170.74−1.830.5021.160.59−2.290.6591.420.57−3.550.4491.500.54−4.160.4311.380.53−3.560.507
2549 D/I1.120.84−1.500.4421.270.84−1.920.2510.980.57−1.690.9511.130.62−2.080.6840.880.50−1.560.661

Ethnicity
Caucasians 1.030.95−1.120.4491.020.90−1.160.7111.070.93−1.230.3681.070.91−1.260.4211.070.92−1.240.401
Asians1.361.17−1.59<0.0011.461.19−1.79<0.0011.461.12−1.910.0051.721.27−2.31<0.0011.310.99−1.740.061

Method
Non-PCR-PFLP1.040.94−1.140.4531.000.88−1.150.9441.100.94−1.280.2471.110.90−1.360.3441.100.94−1.290.232
PCR-RFLP1.311.13−1.52<0.0011.441.21−1.71<0.0011.321.03−1.700.0291.571.18−2.100.0021.160.90−1.510.243

W: wild allele; M: mutant allele; WW: wild homozygote; WM: heterozygote; MM: mutant homozygote; OR: odds ratio; 95%CI: 95% confidence interval; SNP: single nucleotide polymorphism.